


3.5.2 Revenue generated from consultancy and corporate training during the last five years (INR in Lakhs) [15]

3.5.2.1: Total amount generated from consultancy and corporate training year wise during the last five years (INR in lakhs)

Revenue generated from consultancy during the last five years

Name of the consultant	Name of consultancy project	Consulting/Sponsoring agency with contact details	Year	Revenue generated (INR in Lakhs)
2014-2015				
Dr. Sudeep Gupta	Project no. 119: "A prospective randomised trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IB3 squamous carcinoma of the uterine cervix".	Intramural, Tata Memorial Centre	2014-2015	88.64
Dr. Sudeep Gupta	Project no. 657: An observational phase II study of the efficacy of metronomic chemotherapy in patients with relapsed epithelial ovarian carcinoma with elucidation of its potential mechanisms of action by study of angiogenesis and apoptosis	Intramural, Tata Memorial Centre	2014-2015	1.23
Dr. Sudeep Gupta	Project no. 1015: The dynamics of circulating DNA and nucleosomes and their correlation with myelosuppression following adjuvant, neoadjuvant or palliative chemotherapy for early breast cancer (EBC), locally advanced breast cancer (LABC) and metastatic breast cancer (MBC)	Intramural, Tata Memorial Centre	2014-2015	2.01
Dr. Sudeep Gupta	Project no. 1217: A Prospective, open label, non randomized, cohort study of Paclitaxel pharmacokinetics in women with different Body Mass Index undergoing chemotherapy for breast and ovarian cancer	Intramural, Tata Memorial Centre	2014-2015	1.9
Dr. Sudeep Gupta	Project no. 1319: A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Intramural, Tata Memorial Centre	2014-2015	1.92
Dr. Sudeep Gupta	Project no. 1403: A prospective observational study of Chemotherapy Induced Nausea Vomiting (CINV) in patients receiving Anthracycline based chemotherapy for Breast Cancer"	Thesis	2014-2015	1.92
Dr. Sudeep Gupta	Project no. 774: To study the diagnostic usefulness of novel glycan epitope on MUC1, alternatively spliced isoform MUC1V, 7, 2-3 Sialyltransferase and 7, 2-6 Sialyltransferase in breast cancer patients.	Tashraj Biotechnology Limited	2014-2015	2.84
Dr. Sudeep Gupta	Project no. 1216: Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	BIOQUEST SOLUTIONS PRIVATE LIMITED	2014-2015	2.72
Dr. Sudeep Gupta	Project no. 802: Case Control Observational Study Of The Distribution Of Breast Cancer Subtypes And Associated Clinical Features And Risk Factors Among Women Diagnosed With Breast Cancer presenting to three Urban Indian hospitals.	Ethnic Research Initiative, USA	2014-2015	45.25
Dr. Sudeep Gupta	Project no. 1362: Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence"	Oncostem Diagnostics Private Limited	2014-2015	6.71
Dr. Sudeep Gupta	Project no. 309: A Randomized Open Label, Multicenter, Phase 3 Study of Epoetin Alfa plus standard Supportive Care versus standard Supportive Care in Anemic Patients with Metastatic Breast Cancer Receiving First Line Standard Chemotherapy	Johnson & Johnson Pvt. Ltd.	2014-2015	62.98
Dr. Sudeep Gupta	Project no. 326: An Open Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine In Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and / or Metastatic Breast Cancer	Quintiles Research (India) Pvt. Ltd.	2014-2015	65.08
Dr. Sudeep Gupta	Project no. 336: 26866138-LYM-3001- A randomized, Open-Label, Multicenter Study of VELCADE, with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab Naïve or Sensitive Follicular B-cell Non Hodgkin's Lymphoma	Johnson and Johnson Ltd, India	2014-2015	14.83




PROF. S. D. BANAVALI, MD
 DEAN (ACADEMICS)
 TATA MEMORIAL CENTRE
 MUMBAI - 400 012.

Dr. Sudeep Gupta	Project no. 436: ALTO (CLAP016B2901) "A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patient with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2014-2015	76.73
Dr. Sudeep Gupta	Project no. 665: NeoALTO: BIG1-05/EGF106903: "A randomized, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab their combination plus Paclitaxel in women with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2014-2015	22.24
Dr. Sudeep Gupta	Project no. 693: A phase III trial of Vinflunine + Capecitabine versus Capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant (L00070 IN 305 B0).	Pierre Fabre Medicament	2014-2015	29.57
Dr. Sudeep Gupta	Project no. 717: MO22223-A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab induction therapy	Roche Product (India) Pvt. Ltd.	2014-2015	44.18
Dr. Sudeep Gupta	Project no. 764: A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer	Celltrion INC	2014-2015	16.39
Dr. Sudeep Gupta	Project no. 810: Protocol No. 20060359 - A Randomized, Double-blind, Placebo-controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant treatment for women with early stage breast cancer at high risk of recurrence (D-CARE)	Amgen Technology Pvt. Ltd.	2014-2015	82.19
Dr. Sudeep Gupta	Project no. 868: Protocol Number 20090508- A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	Amgen Technology Pvt. Ltd.	2014-2015	55.89
Dr. Sudeep Gupta	Project no. 904: Protocol no. ML25420- A Multi Centre, Pilot Phase II Trial Assessing The Efficacy And Safety Of Bevacizumab + Gemcitabine + Carboplatin As First Line Treatment For Patients Diagnosed With Triple Negative Metastatic Breast Cancer.	Roche Product (India) Pvt. Ltd.	2014-2015	38.13
Dr. Sudeep Gupta	Project no. 1086: MO25515 An open label, multi centre study to assess the safety of RO5185426 in patients with metastatic melanoma	Roche Product (India) Pvt. Ltd.	2014-2015	22.89
Dr. Sudeep Gupta	Project no. 1209: Protocol No. CRAD001V2201 - BOLERO-6 - A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole"	Novartis Healthcare Pvt. Ltd.	2014-2015	16.8
Dr. Kumar Prabhsh	SCIENTIFIC ADVISORY BOARD	ASTRA ZENECA PHARMA INDIA LTD.	2014-2015	0.4



PROF. S. D. BANAVALI, MD
DEAN (ACADEMICS)
TATA MEMORIAL CENTRE
MUMBAI - 400 012.

2015-2016				
Dr. Sudeep Gupta	Project no. 119: "A prospective randomized trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IB3 squamous carcinoma of the uterine cervix".	Intramural, Tata Memorial Centre	2015-2016	88.64
Dr. Sudeep Gupta	Project no. 657: An observational phase II study of the efficacy of metronomic chemotherapy in patients with relapsed epithelial ovarian carcinoma with elucidation of its potential mechanisms of action by study of angiogenesis and apoptosis	Intramural, Tata Memorial Centre	2015-2016	1.23
Dr. Sudeep Gupta	Project no. 1217: A Prospective, open label, non randomized, cohort study of Paclitaxel pharmacokinetics in women with different Body Mass Index undergoing chemotherapy for breast and ovarian cancer	Intramural, Tata Memorial Centre	2015-2016	1.9
Dr. Sudeep Gupta	Project no. 1319: A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Intramural, Tata Memorial Centre	2015-2016	1.92
Dr. Sudeep Gupta	Project no. 1403: A prospective observational study of Chemotherapy Induced Nausea Vomiting (CINV) in patients receiving Anthracycline based chemotherapy for Breast Cancer"	Thesis	2015-2016	1.92
Dr. Sudeep Gupta	Project no. 168: To study the effects of acute, peri-operative hypoxia on breast cancer biology.	Intramural, Tata Memorial Centre	2015-2016	48.8
Dr. Sudeep Gupta	Project no. 151: Mapping of Breast Cancer "Transitions" to Identify the Underlying Biology of Tumor Progression using Next Generation Sequencing (NGS) Technologies"	Department of Science & Technology	2015-2016	52.28
Dr. Sudeep Gupta	Project no. 1216: Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	BIOQUEST SOLUTIONS PRIVATE LIMITED	2015-2016	2.72
Dr. Sudeep Gupta	Project no. 802: Case Control Observational Study Of The Distribution Of Breast Cancer Subtypes And Associated Clinical Features And Risk Factors Among Women Diagnosed With Breast Cancer presenting to three Urban Indian hospitals.	Ethnic Research Initiative, USA	2015-2016	46.25
Dr. Sudeep Gupta	Project no. 1362: Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence".	Oncostem Diagnostics Private Limited	2015-2016	6.71
Dr. Sudeep Gupta	Project no. 309: A Randomized Open Label, Multicenter, Phase 3 Study of Epoetin Alfa plus standard Supportive Care versus standard Supportive Care in Anemic Patients with Metastatic Breast Cancer Receiving First Line Standard Chemotherapy	Johnson & Johnson Pvt. Ltd.	2015-2016	62.98
Dr. Sudeep Gupta	Project no. 326: An Open Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine In Combination with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and / or Metastatic Breast Cancer	Quintiles Research (India) Pvt. Ltd.	2015-2016	65.08
Dr. Sudeep Gupta	Project no. 436: ALTO (CLAP016B2R01) "A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patient with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2015-2016	76.73
Dr. Sudeep Gupta	Project no. 665: NeoALTO: BIG1-06/EGF106903: "A randomized, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab their combination plus Paclitaxel in women with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2015-2016	22.24




(Handwritten signature)

PROF. S. D. BANAVALI, MD
DEAN (ACADEMICS)
TATA MEMORIAL CENTRE
MUMBAI - 400 012.

Dr. Sudeep Gupta	Project no. 717: MO22223-A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab induction therapy	Roche Product (India) Pvt. Ltd.	2015-2016	44.18
Dr. Sudeep Gupta	Project no. 764: A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Metastatic Breast Cancer	Celltrion INC	2015-2016	16.39
Dr. Sudeep Gupta	Project no. 810: Protocol No. 20060359 - A Randomized, Double-blind, Placebo-controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant treatment for women with early stage breast cancer at high risk of recurrence (D-CARE)	Amgen Technology Pvt. Ltd.	2015-2016	82.19
Dr. Sudeep Gupta	Project no. 868: Protocol Number 20090508- A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	Amgen Technology Pvt. Ltd.	2015-2016	55.89
Dr. Sudeep Gupta	Project no. 904: Protocol no. ML25420- A Multi Centre, Pilot Phase II Trial Assessing The Efficacy And Safety Of Bevacizumab + Gemcitabine + Carboplatin As First Line Treatment For Patients Diagnosed With Triple Negative Metastatic Breast Cancer.	Roche Product (India) Pvt. Ltd.	2015-2016	38.13
Dr. Sudeep Gupta	Project no. 1086: MO25515 An open label, multi centre study to assess the safety of RO5185426 in patients with metastatic melanoma	Roche Product (India) Pvt. Ltd.	2015-2016	22.89
Dr. Sudeep Gupta	Project no. 1209: Protocol No. CRAD001Y2201 - BOLERO-6 - A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole	Novartis Healthcare Pvt. Ltd.	2015-2016	16.8
Dr. Sudeep Gupta	Project no. 1532: MO29587-Retrospective Data Collection: Post study treatment anticancer therapy from all randomized patients involved in IMELDA MO22223	Roche Product (India) Pvt. Ltd.	2015-2016	1.6
Dr. Sudeep Gupta	"Redefining the place of eribulin in management of MBC"	Eisai Pharmaceuticals India Pvt. Ltd	2015-2016	0.315
Dr. Sudeep Gupta	Guest speaker in meeting held on 18-Apr-2015 at Tata Memorial Hospital by Bristol-Myers Squibb India Pvt. Ltd	Bristol-Myers Squibb India Pvt. Ltd	2015-2016	0.27
Dr. Kumar Prabhsh	SCIENTIFIC ADVISORY BOARD	ASTRA ZENECA PHARMA INDIA LTD	2015-2016	0.27




 PROF. S. D. BANAVALI, MD
 DEAN (ACADEMICS)
 TATA MEMORIAL CENTRE
 MUMBAI - 400 012.

2016-2017				
Dr. Sudeep Gupta	Project no. 119: "A prospective randomised trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IB3 squamous carcinoma of the uterine cervix".	Intramural, Tata Memorial Centre	2016-2017	88.64
Dr. Sudeep Gupta	Project no. 657: An observational phase II study of the efficacy of metronomic chemotherapy in patients with relapsed epithelial ovarian carcinoma with elucidation of its potential mechanisms of action by study of angiogenesis and apoptosis	Intramural, Tata Memorial Centre	2016-2017	1.23
Dr. Sudeep Gupta	Project no. 1217: A Prospective, open label, non randomized, cohort study of Paclitaxel pharmacokinetics in women with different Body Mass Index undergoing chemotherapy for breast and ovarian cancer	Intramural, Tata Memorial Centre	2016-2017	1.9
Dr. Sudeep Gupta	Project no. 1319: A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Intramural, Tata Memorial Centre	2016-2017	1.92
Dr. Sudeep Gupta	Project no. 1403: A prospective observational study of Chemotherapy Induced Nausea Vomiting (CINV) in patients receiving Anthracycline based chemotherapy for Breast Cancer"	Thesis	2016-2017	1.92
Dr. Sudeep Gupta	Project no. 168: To study the effects of acute, peri-operative hypoxia on breast cancer biology.	Intramural, Tata Memorial Centre	2016-2017	48.8
Dr. Sudeep Gupta	Project no. 187: Exploring the utility of circulating tumor DNA in monitoring response to therapy and in aiding follow up of breast cancer patients using the neoadjuvant setting as a model	Intramural, Tata Memorial Centre	2016-2017	47.37
Dr. Sudeep Gupta	Project no. 151: Mapping of Breast Cancer "Transitions" to identify the Underlying Biology of Tumor Progression using Next Generation Sequencing (NGS) Technologies"	Department of Science & Technology	2016-2017	52.28
Dr. Sudeep Gupta	Project no. 1216: Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	BIOQUEST SOLUTIONS PRIVATE LIMITED	2016-2017	2.72
Dr. Sudeep Gupta	Project no. 802: Case Control Observational Study Of The Distribution Of Breast Cancer Subtypes And Associated Clinical Features And Risk Factors Among Women Diagnosed With Breast Cancer presenting to three Urban Indian hospitals.	Ethnic Research Initiative, USA	2016-2017	46.25
Dr. Sudeep Gupta	Project no. 1362: Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence".	Oncostem Diagnostics Private Limited	2016-2017	6.71
Dr. Sudeep Gupta	Project no. 309: A Randomized Open Label, Multicenter, Phase 3 Study of Epoetin Alfa plus standard Supportive Care versus standard Supportive Care in Anemic Patients with Metastatic Breast Cancer Receiving First Line Standard Chemotherapy	Johnson & Johnson Pvt. Ltd.	2016-2017	62.98
Dr. Sudeep Gupta	Project no. 436: ALTO (CLAP01682801) "A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patient with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2016-2017	76.73
Dr. Sudeep Gupta	Project no. 665: NeoALTYD- BIG1-06/EGF106903: "A randomized, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab their combination plus Paclitaxel in women with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2016-2017	22.24
Dr. Sudeep Gupta	Project no. 717: MO22223-A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab induction therapy	Roche Product (India) Pvt. Ltd.	2016-2017	44.18
Dr. Sudeep Gupta	Project no. 810: Protocol No. 20060359 - A Randomized, Double-blind, Placebo-controlled, (Multi-Center Phase 3 Study of Denosumab as Adjuvant treatment for women with early stage breast cancer at high risk of recurrence [D-CARE]	Amgen Technology Pvt. Ltd.	2016-2017	82.19



(Signature)
 PROF. S. D. BANAVALI, MD
 DEAN (ACADEMICS)
 TATA MEMORIAL CENTRE
 MUMBAI - 400 012.

Dr. Sudeep Gupta	Project no. 868: Protocol Number 20090508- A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	Amgen Technology Pvt. Ltd.	2016-2017	55.89
Dr. Sudeep Gupta	Project no. 1209: Protocol No. CRAD001Y2201 - BOLERO-6 - A three-arm, randomized, open label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenopausal women with estrogen receptor positive, locally advanced, recurrent, or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole"	Novartis Healthcare Pvt. Ltd.	2016-2017	16.8
Dr. Sudeep Gupta	Project no. 1579: Protocol No. - ML29282 : ML29282 -A Phase IV, Multicenter, Open-Label, Single-Arm Study Of Pertuzumab [In Combination With Trastuzumab And Docetaxel] In First Line Treatment Of Indian Patients With Her2-Positive Advanced (Metastatic Or Locally Recurrent) Breast Cancer	Roche Product (India) Pvt. Ltd.	2016-2017	87.58
Dr. Sudeep Gupta	Project no. 1628: CAPCYR07568/ METRO- ABC "A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses /Regimens with Metronomic Schedule in Patients with Metastatic Breast Cancer"	Sanofi Synthelabo (India) Private Limited	2016-2017	2.46
Dr. Sudeep Gupta	Project no. 1660: Protocol No. ML29662- A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients with Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer who have received Prior Treatment with Trastuzumab and a Taxane	Roche Product (India) Pvt. Ltd.	2016-2017	34.14
Dr. Kumar Prabhash	SCIENTIFIC ADVISORY BOARD	Bristol-Myers Squibb India Pvt. Ltd	2016-2017	0.36



PROF. S. D. BANAVALI, MD
DEAN (ACADEMICS)
TATA MEMORIAL CENTRE
MUMBAI - 400 012.


2017-2018				
Dr. Sudeep Gupta	Project no. 119: "A prospective randomised trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IIIB squamous carcinoma of the uterine cervix".	Intramural, Tata Memorial Centre	2017-2018	88.64
Dr. Sudeep Gupta	Project no. 1217: A Prospective, open label, non randomized, cohort study of Paclitaxel pharmacokinetics in women with different Body Mass Index undergoing chemotherapy for breast and ovarian cancer	Intramural, Tata Memorial Centre	2017-2018	1.9
Dr. Sudeep Gupta	Project no. 1319: A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Intramural, Tata Memorial Centre	2017-2018	1.92
Dr. Sudeep Gupta	Project no. 1403: A prospective observational study of Chemotherapy Induced Nausea Vomiting (CINV) in patients receiving Anthracycline based chemotherapy for Breast Cancer"	Thesis	2017-2018	1.92
Dr. Sudeep Gupta	Project no. 168: To study the effects of acute, peri-operative hypoxia on breast cancer biology.	Intramural, Tata Memorial Centre	2017-2018	48.8
Dr. Sudeep Gupta	Project no. 187: Exploring the utility of circulating tumor DNA in monitoring response to therapy and in aiding follow up of breast cancer patients using the neoadjuvant setting as a model	Intramural, Tata Memorial Centre	2017-2018	47.37
Dr. Sudeep Gupta	Project no. 151: Mapping of Breast Cancer "Transitions" to Identify the Underlying Biology of Tumor Progression: using Next Generation Sequencing (NGS) Technologies"	Department of Science & Technology	2017-2018	52.28
Dr. Sudeep Gupta	Project no. 239: Multi-Omics Analysis to Decipher Mechanisms of Hormone Resistance in Breast Cancer	Department of Biotechnology	2017-2018	47.15
Dr. Sudeep Gupta	Project no. 1216: Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	BIOQUEST SOLUTIONS PRIVATE LIMITED	2017-2018	2.72
Dr. Sudeep Gupta	Project no. 802: Case Control Observational Study Of The Distribution Of Breast Cancer Subtypes And Associated Clinical Features And Risk Factors Among Women Diagnosed With Breast Cancer presenting to three Urban Indian hospitals.	Ethnic Research Initiative, USA	2017-2018	46.25
Dr. Sudeep Gupta	Project no. 1362: Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence".	Oncostem Diagnostics Private Limited	2017-2018	6.71
Dr. Sudeep Gupta	Project no. 436: ALTD (CLAP01682301) "A randomized, multi-centre, open-label, phase III study of a tjuvant lapatinib, trastuzumab, their sequence and their combination in patient with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2017-2018	76.73
Dr. Sudeep Gupta	Project no. 665: NeoALTD: BIG1-06/EGF106903: "A randomized, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab their combination plus Paclitaxel in women with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2017-2018	22.24
Dr. Sudeep Gupta	Project no. 810: Protocol No. 20060359 - A Randomized, Double-blind, Placebo-controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant treatment for women with early stage breast cancer at high risk of recurrence (D-CARE)	Amgen Technology Pvt. Ltd.	2017-2018	82.19
Dr. Sudeep Gupta	Project no. 1579: Protocol No. - ML29282 : ML29282 -A Phase IV, Multicenter, Open-Label, Single-Arm Study Of Pertuzumab (In Combination With Trastuzumab And Docetaxel) In First Line Treatment Of Indian Patients With Her2-Positive Advanced (Metastatic Or Locally Recurrent) Breast Cancer	Roche Product (India) Pvt. Ltd.	2017-2018	87.58
Dr. Sudeep Gupta	Project no. 1660: Protocol No. ML29562 - A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtrastine in Indian Patients with Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer who have received Prior Treatment with Trastuzumab and a Taxane	Roche Product (India) Pvt. Ltd.	2017-2018	34.14
Dr. Sudeep Gupta	Project no. 1706: Protocol No. - CBYL719C2301 : A phase III randomized double-blind, placebo controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment	Novartis Healthcare Pvt. Ltd.	2017-2018	8.21
Dr. Kumar Prabhsh	SCIENTIFIC ADVISORY BOARD	Bristol-Myers Squibb India Pvt. Ltd	2017-2018	0.28




 PROF. S. D. BANAVALI, MD
 DEAN (ACADEMICS)
 TATA MEMORIAL CENTRE
 MUMBAI - 400 012.


2018-2019				
Dr. Sudeep Gupta	Project no. 119: "A prospective randomised trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IBB squamous carcinoma of the uterine cervix".	Intramural, Tata Memorial Centre	2018-2019	88.64
Dr. Sudeep Gupta	Project no. 1217: A Prospective, open label, non randomized, cohort study of Paclitaxel pharmacokinetics in women with different Body Mass Index undergoing chemotherapy for breast and ovarian cancer	Intramural, Tata Memorial Centre	2018-2019	1.9
Dr. Sudeep Gupta	Project no. 1319: A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Intramural, Tata Memorial Centre	2018-2019	1.92
Dr. Sudeep Gupta	Project no. 1403: A prospective observational study of Chemotherapy Induced Nausea Vomiting (CINV) in patients receiving Anthracycline based chemotherapy for Breast Cancer"	Thesis	2018-2019	1.92
Dr. Sudeep Gupta	Project no. 168: To study the effects of acute, peri-operative hypoxia on breast cancer biology.	Intramural, Tata Memorial Centre	2018-2019	48.8
Dr. Sudeep Gupta	Project no. 187: Exploring the utility of circulating tumor DNA in monitoring response to therapy and in aiding follow up of breast cancer patients using the neoadjuvant setting as a model	Intramural, Tata Memorial Centre	2018-2019	47.37
Dr. Sudeep Gupta	Project no. 272: To study the role of Activator protein -1 (AP-1) in surgery generated hypoxia stress.	Intramural, Tata Memorial Centre	2018-2019	13.5
Dr. Sudeep Gupta	Project no. 151: Mapping of Breast Cancer "Transitions" to identify the Underlying Biology of Tumor Progression using Next Generation Sequencing (NGS) Technologies"	Department of Science & Technology	2018-2019	52.28
Dr. Sudeep Gupta	Project no. 239: Multi-Omics Analysis to Decipher Mechanisms of Hormone Resistance in Breast Cancer	Department of Biotechnology	2018-2019	47.15
Dr. Sudeep Gupta	Project no. 1965: Pilot study to evaluate the biodistribution & dosimetry of ¹⁷⁷ Lu - Trastuzumab in HER2 receptor positive metastatic breast carcinoma and its toxicity & efficacy profile.	Intramural, Tata Memorial Centre	2018-2019	25.46
Dr. Sudeep Gupta	Project no. 1216: Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	BIOQUEST SOLUTIONS PRIVATE LIMITED	2018-2019	2.72
Dr. Sudeep Gupta	Project no. 802: Case Control Observational Study Of The Distribution Of Breast Cancer Subtypes And Associated Clinical Features And Risk Factors Among Women Diagnosed With Breast Cancer presenting to three Urban Indian hospitals.	Ethnic Research Initiative, USA	2018-2019	46.25
Dr. Sudeep Gupta	Project no. 1362: Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence".	Oncostem Diagnostics Private Limited	2018-2019	6.71
Dr. Sudeep Gupta	Project no. 436: ALTTO (CLAP016B2901) "A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patient with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2018-2019	76.73
Dr. Sudeep Gupta	Project no. 665: NeoALTTO: BIG1-06/EGF106903: "A randomized, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab their combination plus Paclitaxel in women with HER2/ErbB2 positive primary breast cancer"	Novartis Healthcare Pvt. Ltd.	2018-2019	22.24




 PROF. S. D. BANAVALI, MD
 DEAN (ACADEMICS)
 TATA MEMORIAL CENTRE
 MUMBAI - 400 012.

Dr. Sudeep Gupta	Project no. 1579: Protocol No. - ML29282 : ML29282 -A Phase IV, Multicenter, Open-Label, Single-Arm Study Of Pertuzumab (In Combination With Trastuzumab And Docetaxel) In First Line Treatment Of Indian Patients With Her2-Positive Advanced (Metastatic Or Locally Recurrent) Breast Cancer	Roche Product (India) Pvt. Ltd.	2018-2019	87.58
Dr. Sudeep Gupta	Project no. 1660: Protocol No. ML29662- A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine In Indian Patients with Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer who have received Prior Treatment with Trastuzumab and a Taxane	Roche Product (India) Pvt. Ltd.	2018-2019	34.14
Dr. Sudeep Gupta	Project no. 1706: Protocol No. - CBYL719C2301 : A phase III randomized double-blind, placebo controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment	Novartis Healthcare Pvt. Ltd.	2018-2019	8.21
Dr. Sudeep Gupta	Project no. 1978: Protocol No. - MO39196 : MO39196 "A Phase III, Multicentre, randomized, double-blind, two-arm, placebo controlled study designed to evaluate the efficacy and safety of Atezolizumab (an anti-PD-L1 antibody) administered in combination with paclitaxel compared with placebo in combination with paclitaxel in patients with previously untreated, inoperable locally advanced or metastatic, centrally confirmed TNBC	Roche Product (India) Pvt. Ltd.	2018-2019	9.85
Dr. Sudeep Gupta	Project no. 2000: - Protocol no: 471-13 : "A Prospective, Adaptive, Randomized, Open-Label, Multicenter Clinical Trial to assess the Efficacy and Safety of Fixed Dose Combination of Capecitabine & Cyclophosphamide In Patients of Metastatic Breast Cancer with failure of Anthracycline and/or Taxane Chemotherapy	Intas Pharmaceuticals Ltd.	2018-2019	72.76
Dr. Sudeep Gupta	Protocol no 3047: 1000-16 "An Open Label, Single Arm, Multicentric, Phase IV study to evaluate the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited in approved indications"	Intas Pharmaceuticals Ltd.	2018-2019	20.33
Dr. Sudeep Gupta	Project no. 3070: Protocol No: D0818R00001 "A Non-interventional, multicentre study to assess prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in India (BRCA STUDY)"	AstraZeneca Pharma India Ltd.	2018-2019	3.24
Dr. Sudeep Gupta	Project no. 3098: EIL-E7389-CT01-012 "Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Breast Cancer"	Eisai Pharmaceuticals India Private Limited	2018-2019	6.75
Dr. Sudeep Gupta	Project no. 3099: ECTS/16/002 A multicentre, open label clinical trial in two stages: Stage I - Evaluating the response rate of ormeloxifene and Stage II - Comparing the safety, efficacy and tolerability of ormeloxifene versus letrozole + ovarian suppression therapy in tamoxifen-resistant metastatic/recurrent breast cancer patients.	HLL Lifecare Ltd	2018-2019	3.92
Dr. Sudeep Gupta	Project no. 3112: 0063-17 "A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy."	Intas Pharmaceuticals Ltd.	2018-2019	4.9
Dr. Sudeep Gupta	"PARP inhibitors beyond BRCA in the maintenance Therapy of Ovarian Cancer: A new horizon in PSR Ovar"	AstraZeneca Pharma India Ltd.	2018-2019	0.4
Dr. Sudeep Gupta	ESMO Asia ad board meeting at Singapore	AstraZeneca	2018-2019	0.97
Dr. Kumar Prabhsh	SCIENTIFIC ADVISORY BOARD	Bristol-Myers Squibb India Pvt. Ltd	2018-2019	0.33




 PROF. S. D. BANAVALI, MD
 DEAN (ACADEMICS)
 TATA MEMORIAL CENTRE
 MUMBAI - 400 012.



टाटा स्मारक केन्द्र
TATA MEMORIAL CENTRE

टाटा स्मारक अस्पताल
TATA MEMORIAL HOSPITAL

AA No. 1013165

प.ऊ.वि. भारत सरकार का एक सहायता अनुदान प्राप्त संस्थान
A GRANT-IN-AID INSTITUTE OF THE DEPARTMENT OF ATOMIC ENERGY, GOVT. OF INDIA

Annexure-II

Ref:

August 7, 2020

The list of revenue generated from consultancy and corporate training during the last five years in respect of Tata Memorial Centre (name of the institute), a Constituent Institution/ Off Campus Centre of HBNI is enclosed herewith.

Director/ Registrar

(Signature)

Encl: As above

Seal



PROF. S. D. BANAVALI, MD
DEAN (ACADEMICS)
TATA MEMORIAL CENTRE
MUMBAI - 400 012.

Dr. E. Borges Marg, Parel
Mumbai - 400 012, India.
Phone: +91-22-2417 7000
Fax: +91-22-2414 6937

डॉ. ई. बोर्जेस मार्ग, परेल,
मुंबई - ४०० ०१२, भारत.
दूरभाष : +९१-२२-२४१७ ७०००
फैक्स : +९१-२२-२४१४ ६९३७

Cancer is curable, if detected early.

Website : <https://tmc.gov.in>

जल्द इलाज होने पर कैंसर ठीक हो सकता है ।